CBX-14

CBX-14 is a preclinical-stage small molecule inhibitor targeting the DNA damage response (DDR) pathway, developed by Cybrexa Therapeutics. While Cybrexa is primarily recognized for its alphalex™ platform, which utilizes pH-sensitive peptides to deliver payloads specifically to the acidic tumor microenvironment, CBX-14 is identified in company pipeline disclosures as a standalone small molecule therapeutic. The specific protein target within the DDR machinery (such as ATR, ATM, or DNA-PK) has not been publicly specified. The drug is designed to exploit genomic repair vulnerabilities in cancer cells, potentially inducing synthetic lethality or sensitizing tumors to other DNA-damaging agents. It may also serve as the functional inhibitor component for subsequent alphalex-conjugated assets, such as CBX-15.